CLGN | tickerfilter.com

Fundamental analysis

13%

Profitability 18%

Dept financing 25%

Liquidity 31%

Performance 0%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-2.03%

1 Month

-23.97%

3 Months

-42.60%

6 Months

-47.03%

1 Year

-53.88%

2 Year

-67.23%

Key data

Stock price

$2.41

P/E Ratio

0.00

DAY RANGE

$2.38 - $2.45

EPS

-$1.31

52 WEEK RANGE

$2.20 - $6.75

52 WEEK CHANGE

-$54.01

MARKET CAP

71.482 M

YIELD

N/A

SHARES OUTSTANDING

11.455 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-28-2025

BETA

0.47

PUBLIC FLOAT

AVERAGE 10 VOLUME

$8,716

AVERAGE 30 VOLUME

$13,171

Company detail

CEO: Yehiel Tal
Region: US
Website: collplant.com
Employees: 70
IPO year: 2018

Issue type: Common Stock
Market: XNAS
Industry: Medical Equipment/Surgical, Medical, And Dental Instruments And Supplies
Sector: Manufacturing

CollPlant Biotechnologies Ltd. focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie.

CLGN - CollPlant Biotechnologies Ltd